Engflag

Flavospas O

Quick links to important sections

Flavospas O

Flavospas O_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flavospas O

Property Description
Active ingredients Flavoxate, Ofloxacin
Form Oral tablet
Pharmacological class Combination antispasmodic and antimicrobial agent
General purpose To treat both infection and associated muscle spasms in the urinary tract
Origin Synthetic

What Type of Medicine is Flavospas O?

Flavospas O is defined as a combination synthetic prescription medicine delivered as an oral tablet. This formulation is classified as belonging to two distinct pharmacological categories: a fluoroquinolone antimicrobial and a urinary antispasmodic.

Its composition is engineered to deliver simultaneous therapeutic action, providing a comprehensive approach for conditions affecting the lower urinary tract where both microbial presence and muscle hyperactivity are central factors. The medicine's dual nature is characterized as an effective strategy when both infection clearance and symptomatic relief are required. This combination type is often utilized when managing complex urinary tract symptoms.

Composition and Purpose of the Dual-Action Formulation

This medicine’s composition includes the two active ingredients, Ofloxacin and Flavoxate. Ofloxacin is a broad-spectrum antibiotic that exhibits a bactericidal effect, working by inhibiting essential bacterial enzymes needed for DNA replication. This function is clinically recognized for its efficacy against a range of common uropathogens.

The other component, Flavoxate, is categorized as an antimuscarinic agent that functions primarily as a spasmolytic. The combination's primary therapeutic purpose is to offer an integrated approach: Ofloxacin clears the bacterial source of the infection, while Flavoxate works to calm the muscular contractions of the irritated bladder, providing general relief from the uncomfortable symptoms often associated with urinary tract issues. Other products sharing this dual formulation are similarly designed to combine these two mechanisms for integrated relief.

Regulatory References

  1. Flavoxate Drug Information (MedlinePlus)

What side effects are possible with Flavospas O?

Possible side effects and safety information

The official safety profile for this combination medicine, which includes an antispasmodic and the fluoroquinolone Ofloxacin, is documented by regulatory authorities (e.g., FDA, EMA) and is classified across several body systems.

Adverse reactions are formally categorized by frequency. Common reactions often involve Gastrointestinal Disorders, such as nausea, vomiting, or diarrhea, and Nervous System Disorders, including headache and dizziness. Less frequent or Uncommon reactions may include dry mouth, visual disturbances, or skin rash.

Serious Adverse Reactions

Specific warnings are documented for the Ofloxacin component concerning serious and potentially permanent adverse reactions. These include tendinitis and tendon rupture, particularly affecting the Achilles tendon, and peripheral neuropathy (a type of nerve damage). Other serious documented risks involve central nervous system effects, such as seizures or severe psychiatric reactions, and the risk of QT c interval prolongation in the heart.

Safety Considerations and Restrictions

Regulatory documents specify that safety risks may be higher for certain groups; for example, older adults have an officially noted increased risk of tendon disorders. The medicine is formally restricted for individuals with pre-existing conditions related to the antispasmodic component, such as obstructive uropathies or obstructive intestinal lesions. Furthermore, tendon disorders associated with Ofloxacin may occur not only during treatment but up to several months after discontinuation, a time-related safety pattern officially included in regulatory labeling.

Overdose and Emergency Response

The official regulatory documentation for the active components of Flavospas O defines the overdose profile through distinct toxicological risks primarily affecting the Central Nervous System, cardiovascular system, and metabolic processes.

Overdose Manifestations and Severe Outcomes

Overdose presentations documented for the antispasmodic component may include severe dizziness, severe drowsiness, flushing of the face, fever, hallucinations, and unusual excitement or irritability. The antimicrobial component is associated with more severe outcomes, including seizures (convulsions), QT interval prolongation, and disturbances in blood glucose, potentially leading to hypoglycemic coma.

When to Seek Immediate Medical Help

The official label mandates seeking immediate medical attention if serious symptoms of low blood sugar are observed, specifically citing manifestations such as confusion, blurred vision, loss of consciousness, or seizures. If severe neurological events or psychiatric reactions occur, the medicine must be discontinued, and appropriate measures should be instituted as part of supportive care. Elderly patients and individuals with diabetes are a population noted in regulatory documents as having an increased risk for serious hypoglycemia in potential overdose scenarios. Due to the lack of a known specific antidote, management is directed toward providing symptomatic and supportive treatment.

Therapeutic Uses of Flavospas O

What Flavospas O Treats: Main Uses and Benefits

The active ingredients in Flavospas O are utilized in the management of certain symptoms related to the urinary tract. These components are applied in addressing symptom clusters that may become intense or disruptive, especially those linked to the lower urinary tract, such as dysuria (painful urination), urgency, nocturia (waking at night to urinate), frequency, suprapubic pain, and incontinence.

Therapeutic Focus

Flavospas O plays a role in managing conditions characterized by periods of heightened symptoms where short-term symptomatic assistance is needed. The supportive relief offered may help with symptom fluctuations and supports general well-being during symptomatic phases. It is commonly used during phases of increased distress or discomfort when symptoms associated with functional instability become more noticeable, providing support that helps ease the overall symptom burden.

Quick Fact: Supportive Management for Disruptive Urinary Symptoms

Regulatory References

  1. US National Library of Medicine (NIH) DailyMed Information

Eligibility and Restrictions for Use

Eligibility Profile for Flavospas O (Official Regulatory Information)

This medication is a fixed-dose combination and its use is strictly governed by the restrictions for both its components (Flavoxate and Ofloxacin).

Eligibility Scope Status Populations/Conditions
Contraindicated (Must Not Use) Absolute Prohibition Known hypersensitivity to components, Myasthenia Gravis, history of tendinitis/tendon rupture related to fluoroquinolones, epilepsy or lowered seizure threshold.
Obstructive Conditions Achalasia, pyloric or duodenal obstruction, gastrointestinal hemorrhage, obstructive uropathies (urinary retention), and Glaucoma.
Age Restriction Not Recommended Children under 12 years; safety and efficacy are not established in this age group.
Reproductive Status Not Recommended Pregnant and breastfeeding women; use is generally contraindicated or advised against.
Conditional Use (Requires Caution) Restriction Elderly patients (over 60 years) due to increased CNS effect risk; patients with renal or hepatic impairment (dose adjustment may be needed).

The regulatory profile prohibits the use of Flavospas O in a range of patients defined by severe clinical conditions or vulnerability. The approved population is generally limited to adults and adolescents aged 12 and over who are free of these specific absolute contraindications and physical obstructions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines documented interactions primarily related to the product's fluoroquinolone (Ofloxacin) and anticholinergic (Flavoxate) components.

Pharmacokinetic and Absorption Constraints

Certain products containing metal cations can significantly reduce the absorption and efficacy of Ofloxacin. Antacids (aluminum or magnesium-containing), Sucralfate, iron or zinc supplements, and Didanosine chewable/buffered tablets should not be taken within a two-hour period before or after taking this medicine. Similarly, concomitant intake of dairy products may inhibit Ofloxacin absorption and should be avoided.

Pharmacodynamic and Safety Interactions

Caution is required when co-administering with drugs known to prolong the QT interval, as this combination may increase the risk of QTc prolongation, especially in patients with existing cardiac risk factors. The use of certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), specifically fenbufen or similar agents, alongside Ofloxacin may increase the risk of central nervous system excitability.

Interactions Affecting Drug Levels

Interactions are documented with several medicines due to potential alterations in elimination or metabolism. Caution is advised when used with certain antidiabetic agents, such as Glibenclamide, due to the risk of altered blood glucose levels, including hypoglycemia. Medicines like Probenecid, Cimetidine, and Furosemide may affect the renal elimination of Ofloxacin, potentially increasing its systemic concentration. Close monitoring is also necessary when this product is used concurrently with Vitamin K antagonists.

Mechanism of Action

How Flavospas O Works: Dual Pharmacodynamic Mechanism

Flavospas O exerts its action through two independent pharmacological mechanisms focused on smooth muscle signaling and bacterial enzyme inhibition.

Modulation of Smooth Muscle Contraction (Flavoxate)

This component involves a direct action on urinary smooth muscle cells by engaging regulatory mechanisms that govern involuntary muscle tone. The mechanism is attributed to influencing intracellular signaling, likely through the inhibition of phosphodiesterase (PDE) and the modulation of calcium channel activity. This interaction limits the ion flow necessary for muscle contraction. The resulting mechanistic activity induces a state of cellular relaxation and reduces the frequency of contractile signaling, contributing to a measurable physiological adjustment of smooth muscle tone in the urinary tract.

Inhibition of Bacterial DNA Replication (Ofloxacin)

The antibacterial component targets essential microbial machinery by inhibiting key bacterial enzymes, specifically DNA gyrase (topoisomerase II) and topoisomerase IV. This binding blocks the necessary processes of DNA uncoiling, repair, and replication within the bacterial cell. This inhibition initiates a bactericidal mechanistic cascade leading to rapid and irreversible damage to the bacterial genome, which results in bacterial cell death.

Dosage and Administration Information

The administration of the combination drug Flavospas O follows specific principles for its two active components. The medicine is intended solely for oral administration as a tablet, adhering to the standard route outlined in prescribing information.

Usage is structured by a requirement for divided daily dosing. For the antispasmodic component (Flavoxate), the regimen typically involves taking the prescribed dose, which ranges from 100 mg to 200 mg per dose, three to four times a day. The Ofloxacin component, a fluoroquinolone antimicrobial, may be administered without regard to meals, simplifying the overall daily schedule for the patient.

Parameters include specific dose adjustments based on two key factors. First, the dose of the symptomatic component may be reduced once clinical improvement is noted. Second, a dosage adjustment is necessary for the Ofloxacin component when treating adult patients with impaired renal function (creatinine clearance rate below 50 mL/min). Furthermore, the Flavoxate component is not recommended for use in children under 12 years of age, reflecting specific age-related administration constraints. This protocol describes the application of the medicine within its therapeutic framework.

Recent Clinical Evidence

Research Evidence Overview for Flavospas O

This section provides a summary of the clinical research conducted for Flavospas O, outlining what has been studied and where the existing evidence has recognized limitations. The medicine is a combination of two active ingredients, and the research often addresses each component's potential function in conditions of the lower urinary tract.

Types of Studies Used to Evaluate the Combination

Research relevant to Flavospas O includes several types of studies. For the component aimed at clearing infection, researchers relied on Randomized Controlled Trials (RCTs). These studies were evaluated in adults and compared the antibiotic component to other standard agents for different types of urinary tract infections (UTIs). For the component addressing muscle contractions and pain, the evidence primarily includes Double-Blind, Placebo-Controlled Trials and Systematic Reviews. These studies research examined how the antispasmodic component affected patient-reported outcomes describing perceived discomfort related to bladder symptoms. This overall evidence was studied for its relevance in examining dual therapeutic goals.

Evidence for Use in Urinary Tract Infections with Associated Spasms

The primary research focus for this combination medicine was evaluated in conditions associated with acute or disruptive episodes in the lower urinary tract where both infection and bothersome muscle activity are present. Research was studied for its ability to address both the microbial cause and the irritating symptoms at the same time. Trials studies explored two main types of outcomes: outcomes related to pathogen clearance, which measured the elimination of the specific bacteria causing the infection (known as bacteriological cure), and symptomatic outcomes, which measured changes in specific bothersome symptoms such as dysuria (painful urination), urgency, frequency, and nocturia (waking at night to urinate). These studies were applied in research contexts involving fluctuating or unstable symptoms in adults.

Long-Term Studies and Follow-Up

The majority of the available research on infection clearance research explored short-term symptom changes over a defined time interval. The follow-up durations were limited to the end of the acute treatment phase (usually 3 to 14 days) and a short period afterward to check for resolution. As a result, the long-term effects are not fully established for this medicine. Research has provided limited insight into whether symptomatic relief is sustained over many months, and evidence is limited regarding the stability or recurrence patterns of the underlying conditions.

What is Still Uncertain About Flavospas O

While the evidence contributes to the broader evidence landscape for dual-action therapy, several limitations in the research structure remain. The primary uncertainty stems from a comparative evidence is lacking for the fixed-dose combination itself. Researchers have not widely published direct comparative trials that measure the outcome of taking the combination drug versus taking only the antibiotic component. This means the overall evidence level for the dual-action approach was designated as moderate because the available data relies heavily on the results of separate trials for each active ingredient.

Key Studies & References Flavoxate in the symptomatic treatment of overactive bladder: a meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Flavospas O (FAQ)

Q: How long will I be on this medication?

The official product information does not specify a maximum duration. The length of treatment is a decision made by the prescribing healthcare provider based on the condition being treated. Studies that evaluated the antibiotic component of this drug for infection clearance were typically short-term, with treatment phases often lasting between 3 and 14 days.

Q: Are there any known drug-drug or food-drug interactions with Flavospas O?

Yes, official labels note several interactions. Foods like dairy products and medicines such as antacids or supplements containing iron or zinc can reduce the absorption of the Ofloxacin component. Additionally, using this medicine with alcohol may increase nervous system side effects like dizziness due to the Flavoxate component.

Q: What should I do if I take too much Flavospas O (overdose)?

Regulatory information describes potential symptoms of an overdose, which may include dizziness, confusion, nausea, or slurred speech. In the event of a suspected overdose, prompt medical attention is necessary.

Q: What are the most common side effects of Flavospas O?

Regulatory documents state that common adverse reactions typically affect the stomach and digestive system, such as nausea, vomiting, or diarrhea (Gastrointestinal Disorders). Other frequently reported side effects involve the nervous system, including headache and dizziness.

Q: What happens if I miss a dose of Flavospas O?

If a dose is missed, regulatory guidance suggests taking it as soon as it is remembered. However, if it is almost time for your next scheduled dose, skip the missed dose completely. It is advised not to double the dose to make up for a forgotten one.

Q: Can I take Flavospas O with alcohol?

Official labeling suggests caution regarding alcohol consumption. Alcohol can increase the side effects of the Flavoxate component, which may include central nervous system effects such as drowsiness, dizziness, and difficulty concentrating.

Q: What is the generic name for Flavospas O?

Flavospas O is the brand name. It is a combination medication containing two different generic active ingredients: Flavoxate hydrochloride (an antispasmodic) and Ofloxacin (an antimicrobial antibiotic).

Q: How quickly does Flavospas O start working?

Based on regulatory clinical pharmacology data for the Flavoxate component, the antispasmodic effect on the bladder muscle was observed to begin in less than an hour, with the maximum effect generally occurring about two hours after taking the medicine.

How should Flavospas O be stored and disposed of?

How to Store and Dispose of Flavospas O

Flavospas O tablets must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), with storage below 30 C being a key requirement. The product must be kept in its original container and maintained tightly closed to ensure stability.

Regulatory labeling requires that the tablets be protected from light, excess heat, and moisture. It is also mandatory to keep this medication out of the sight and reach of children and to keep it from freezing to preserve product efficacy.

For disposal, do not flush unused or expired Flavospas O down the toilet or pour it into a drain. The correct protocol is to dispose of the product through a community drug take-back program or by following specific household disposal instructions provided by your healthcare professional or local waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Flavospas O found in:

A-Z Index: